From Reform to Delivery: Five priorities for embedding commercial clinical trials excellence across the NHS
November 2026
To mark London Life Sciences Week, MSD is launching a new report setting out five priorities to help strengthen the delivery of commercial clinical trials across the UK.
MSD is committed to supporting the UK’s continued success as a destination for commercial clinical research. At any one time, MSD conducts approximately 150 clinical trials in the UK, with around 2,000 patients participating each year. With this significant UK footprint, MSD is working with the wider clinical research community to consider how the UK can build on recent progress and further strengthen trial delivery for patients and the NHS.
The UK has made encouraging progress in clinical trial set-up, supported by recent policy and system reforms. The opportunity now is to build on this progress and ensure the next phase of reform supports successful recruitment and effective delivery from trial set-up through to completion. To explore what this should look like in practice, MSD convened a roundtable in September 2026, From commitment to delivery: embedding clinical trial reform across the NHS. Chaired by former NHS England Chief Strategy Officer Chris Hopson, the discussion brought together stakeholders from across the clinical research system to consider the priorities for strengthening commercial clinical trial delivery across the UK.
Drawing on insights from the roundtable, the report identifies five priorities to help inform the next phase of clinical trial reform. Together, they focus on building on improvements in trial set-up to support successful recruitment and delivery at scale.
Five priorities for the next phase of clinical trial reform
- The next phase of clinical trial reform should shift from measuring how quickly trials open to measuring how effectively they are delivered.
- Clinical trial recruitment should be given the same sustained national focus that has been applied to trial set-up and activation, supported by a coordinated national approach to improving recruitment.
- Better use of health data can support more effective trial recruitment and delivery.
- Commercial research should be more firmly embedded as a core part of NHS delivery, with greater NHS executive and board-level ownership of research performance and its contribution to organisational priorities.
- The development of more flexible, system-wide models of trial delivery could expand research capacity beyond established research-intensive centres.
Building on the UK’s clinical research momentum
Taken together, the recommendations provide a practical foundation for the next phase of clinical trial reform. By strengthening research capacity, improving recruitment, making better use of health data and embedding research more consistently across the NHS, the UK has an opportunity to build a clinical research environment that is more predictable for sponsors, more sustainable for research teams and more accessible for patients.
A strong commercial clinical trials environment can bring benefits beyond research itself, supporting opportunities for patients to participate in innovative research, bringing investment into the UK and building research capability and expertise across the NHS.
MSD is committed to working in partnership with Government, the NHS and the wider research community to help realise this ambition. By maintaining the momentum behind reform and focusing collectively on successful delivery, the UK can continue to attract ambitious commercial research, deliver trials effectively at scale and, ultimately, enable more patients to benefit from opportunities to participate in clinical research.
Read the report to explore MSD’s five priorities for embedding commercial clinical trials excellence across the NHS.
GB-NON-13908 | November 2026